Oruka Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Oruka Therapeutics, Inc. (ORKA) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value of $6.03 per share for the 12-month period ending 2017-12-31, per its 10-K filed 2019-02-27.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue · last filed 2019-02-27
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2017-03-31 was $6.03, a 28.57% increase year-over-year.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2016-03-31 was $4.69.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2017 was $6.03, a 28.57% increase from fiscal 2016.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2016 was $4.69, a 56.97% decline from fiscal 2015.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2015 was $10.90.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2017-12-31 | $6.03 10-K · filed 2019-02-27 | |||
| 2017-09-30 | $6.03 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | $6.03 10-Q · filed 2017-08-03 | |||
| 2017-03-31 | $6.03 10-Q · filed 2017-05-15 | |||
| 2016-12-31 | $4.69 10-K · filed 2018-03-22 | |||
| 2016-09-30 | $4.69 10-Q · filed 2016-11-14 | |||
| 2016-06-30 | $4.69 10-Q · filed 2016-08-09 | |||
| 2016-03-31 | $4.69 10-Q · filed 2016-05-11 | |||
| 2015-12-31 | $10.90 10-K · filed 2017-03-21 | |||
| 2015-09-30 | $7.06 10-Q · filed 2015-11-12 | |||
| 2015-06-30 | $1.01 10-Q · filed 2015-08-11 | |||
| 2014-09-30 | $0.00 10-Q · filed 2014-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |